Literature DB >> 16418378

Endovascular treatment of intracerebral arteriovenous malformations: procedural safety, complications, and results evaluated by MR imaging, including diffusion and perfusion imaging.

M Cronqvist1, R Wirestam, B Ramgren, L Brandt, B Romner, O Nilsson, H Säveland, S Holtås, E-M Larsson.   

Abstract

BACKGROUND AND
PURPOSE: Endovascular embolization is an increasingly common method to treat intracerebral arteriovenous malformations (AVM). To date, however, published data are rather scarce, especially with regard to true procedure-related complications and their causes. The purpose of our study was to evaluate treatment safety and correlate anatomic results with clinical outcome by using MR imaging, including diffusion-weighted (DWI) and perfusion imaging (PI).
METHODS: We performed 50 endovascular procedures in 21 patients. Most AVMs were supratentorial, Spetzler-Martin grades II-IV. MR imaging was scheduled within 1 week before and 3 days after each treatment. MR imaging findings were correlated to digital subtraction angiography, procedure reports, and the clinical course. Outcome was graded according to the modified Rankin scale (mRS) 3-6 months after treatment.
RESULTS: In this study, 104 MR imaging examinations were performed; mean interval between the endovascular procedure and posttreatment MR imaging was 28 hours. Nine adverse events occurred in 7 patients during 8 procedures (16%), one causing a permanent deficit. New lesions were noted on MR imaging after 22/50 procedures. Ischemic lesions in 22% of the procedures, frequently located perinidally. Most lesions were small, frequently asymptomatic, and reversible (18/23). Four hematomas were found. Subacute hemorrhages developed from a vasogenic edema on 2 occasions. New lesions, including hematomas, developed between treatments in 4 patients, mainly because of progressive occlusion of the nidus or draining veins. PI overestimated the AVM nidus on most occasions, and transient worsening of the PI pattern was noted in 2 patients. Treatment-related mortality and morbidity were 0% and 14.2%, respectively (mRS 1-2).
CONCLUSIONS: Endovascular procedures are rather safe but are associated with more ischemic events and followed by less hemodynamic disturbances than previously understood. Adverse procedural events and new MR imaging lesions were generally asymptomatic and most often transient, if symptomatic. Most lesions would not have been verified without MR imaging. DWI and PI were most useful to detect and understand the cause of various complications. The most clinically important complications were caused by late venous occlusions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418378      PMCID: PMC7976081     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  59 in total

1.  Diffusion- and perfusion-weighted MRI in therapeutic neurointerventional procedures.

Authors:  M Cronqvist; B Ramgren; B Geijer; R Wirestam; L Brandt; S Holtås
Journal:  Neuroradiology       Date:  2001-08       Impact factor: 2.804

2.  Demographic, morphological, and clinical characteristics of 1289 patients with brain arteriovenous malformation.

Authors:  C Hofmeister; C Stapf; A Hartmann; R R Sciacca; U Mansmann; K terBrugge; P Lasjaunias; J P Mohr; H Mast; J Meisel
Journal:  Stroke       Date:  2000-06       Impact factor: 7.914

3.  Embolization of cerebral arteriovenous malformations: Part I--Technique, morphology, and complications.

Authors:  G Wikholm; C Lundqvist; P Svendsen
Journal:  Neurosurgery       Date:  1996-09       Impact factor: 4.654

4.  Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation.

Authors:  H Mast; W L Young; H C Koennecke; R R Sciacca; A Osipov; J Pile-Spellman; L Hacein-Bey; H Duong; B M Stein; J P Mohr
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

5.  Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis.

Authors:  S Warach; J F Dashe; R R Edelman
Journal:  J Cereb Blood Flow Metab       Date:  1996-01       Impact factor: 6.200

6.  Prediction of obliteration after gamma knife surgery for cerebral arteriovenous malformations.

Authors:  B Karlsson; C Lindquist; L Steiner
Journal:  Neurosurgery       Date:  1997-03       Impact factor: 4.654

7.  A characteristic feature of acute haematomas in the brain on echo-planar diffusion-weighted imaging.

Authors:  N Morita; M Harada; K Yoneda; H Nishitani; M Uno
Journal:  Neuroradiology       Date:  2002-09-20       Impact factor: 2.804

8.  Diffusion- and perfusion-weighted MR imaging of dural sinus thrombosis.

Authors:  J Manzione; G C Newman; A Shapiro; R Santo-Ocampo
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

9.  Effect of age on clinical and morphological characteristics in patients with brain arteriovenous malformation.

Authors:  C Stapf; A V Khaw; R R Sciacca; C Hofmeister; H C Schumacher; J Pile-Spellman; H Mast; J P Mohr; A Hartmann
Journal:  Stroke       Date:  2003-10-23       Impact factor: 7.914

10.  Arteriovenous malformations of the brain: natural history in unoperated patients.

Authors:  P M Crawford; C R West; D W Chadwick; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

View more
  14 in total

1.  Radiosurgical treatment planning of AVM following embolization with Onyx: possible dosage error in treatment planning can be averted.

Authors:  Natan Shtraus; Dan Schifter; Benjamin W Corn; Shimon Maimon; Shlomi Alani; Vladimir Frolov; Diana Matceyevsky; Andrew A Kanner
Journal:  J Neurooncol       Date:  2010-04-10       Impact factor: 4.130

2.  Seizures after Onyx embolization for the treatment of cerebral arteriovenous malformation.

Authors:  K de Los Reyes; A Patel; A Doshi; N Egorova; F Panov; J B Bederson; J A Frontera
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

3.  Measurement of blood flow in arteriovenous malformations before and after embolization using arterial spin labeling.

Authors:  L Suazo; B Foerster; R Fermin; H Speckter; C Vilchez; J Oviedo; P Stoeter
Journal:  Interv Neuroradiol       Date:  2012-03-16       Impact factor: 1.610

4.  Hemorrhagic complications after endovascular treatment of cerebral arteriovenous malformations.

Authors:  H Baharvahdat; R Blanc; R Termechi; S Pistocchi; B Bartolini; H Redjem; M Piotin
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

5.  Spontaneous thrombosis of the main draining vein revealing an unruptured brain arteriovenous malformation.

Authors:  Catherine Cao; Nader Sourour; Vincent Reina; Aurélien Nouet; Federico Di Maria; Jacques Chiras; Philippe Cornu; Frédéric Clarençon
Journal:  Interv Neuroradiol       Date:  2015-05-11       Impact factor: 1.610

Review 6.  Targeted endovascular treatment for ruptured brain arteriovenous malformations.

Authors:  Kun Hou; Kan Xu; Xuan Chen; Tiefeng Ji; Yunbao Guo; Jinlu Yu
Journal:  Neurosurg Rev       Date:  2019-11-13       Impact factor: 3.042

7.  Curative embolization of cerebral arteriovenous malformations (AVMs) with Onyx in 101 patients.

Authors:  Vasilios Katsaridis; Chrysanthi Papagiannaki; Enrico Aimar
Journal:  Neuroradiology       Date:  2008-04-12       Impact factor: 2.804

8.  Complications of Endovascular Treatments for Brain Arteriovenous Malformations: A Nationwide Surveillance.

Authors:  K Sato; Y Matsumoto; T Tominaga; T Satow; K Iihara; N Sakai
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-19       Impact factor: 3.825

Review 9.  Steps to translate preconditioning from basic research to the clinic.

Authors:  Frances R Bahjat; Raffaella Gesuete; Mary P Stenzel-Poore
Journal:  Transl Stroke Res       Date:  2012-11-02       Impact factor: 6.829

10.  Unexpected silent infarctions after embolization of cerebral arteriovenous malformations and fistulas. A diffusion-weighted magnetic resonance imaging study.

Authors:  L Suazo; C Putman; C Vilchez; P Stoeter
Journal:  Interv Neuroradiol       Date:  2013-05-21       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.